SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-24-020973
Filing Date
2024-05-22
Accepted
2024-05-22 09:15:11
Documents
15
Period of Report
2024-05-22
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 44016
2 ex99-1.htm EX-99.1 10366
  Complete submission text file 0001493152-24-020973.txt   274097

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE protageniccom-20240522.xsd EX-101.SCH 3850
4 XBRL DEFINITION FILE protageniccom-20240522_def.xml EX-101.DEF 26736
5 XBRL LABEL FILE protageniccom-20240522_lab.xml EX-101.LAB 36857
6 XBRL PRESENTATION FILE protageniccom-20240522_pre.xml EX-101.PRE 25360
19 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5687
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 (212) 994-8200
Protagenic Therapeutics, Inc.\new (Filer) CIK: 0001022899 (see all company filings)

IRS No.: 061390025 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12555 | Film No.: 24971768
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)